Compare ESPR & ODC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | ODC |
|---|---|---|
| Founded | 2008 | 1941 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Miscellaneous manufacturing industries |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.9M | 895.7M |
| IPO Year | 2013 | 1994 |
| Metric | ESPR | ODC |
|---|---|---|
| Price | $2.31 | $67.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.60 | N/A |
| AVG Volume (30 Days) | ★ 5.3M | 49.6K |
| Earning Date | 05-05-2026 | 03-11-2026 |
| Dividend Yield | N/A | ★ 1.21% |
| EPS Growth | ★ 60.71 | 50.45 |
| EPS | N/A | ★ 1.69 |
| Revenue | $403,135,000.00 | ★ $485,572,000.00 |
| Revenue This Year | $2.92 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $40.15 |
| Revenue Growth | ★ 21.31 | 10.97 |
| 52 Week Low | $0.73 | $41.37 |
| 52 Week High | $4.18 | $70.01 |
| Indicator | ESPR | ODC |
|---|---|---|
| Relative Strength Index (RSI) | 33.99 | 66.86 |
| Support Level | $1.02 | $58.40 |
| Resistance Level | $3.02 | $69.80 |
| Average True Range (ATR) | 0.20 | 1.75 |
| MACD | 0.00 | 0.59 |
| Stochastic Oscillator | 17.40 | 95.14 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.